



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 05/04/2022 14:23  
**Last Report Issued** 05/04/2022 14:23

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 4766SP  
**Patient ID** 4766SP  
**Chain 1**  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 09002992  
**Received** 09/23/2009

**Lab ID** 09002992-001  
**Matrix** Serum or Plasma  
**Patient Name** 4766SP  
**Patient ID** 4766SP  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**4766SP Valacyclovir as Metabolite, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Acyclovir	None Detected	mcg/mL	0.20	
-----------	---------------	--------	------	--

Synonym(s): Valacyclovir Metabolite

For using Acyclovir:  
Usual therapeutic range (vs. Genital Herpes) during  
Chronic oral daily divided dosages of 1200 to 2400 mg:  
Peak: 0.40-2.0 mcg/mL plasma  
Trough: 0.14-1.2 mcg/mL plasma.

For using Valacyclovir as a metabolite:  
Mean steady-state ( +/- 1 SD) peak plasma levels  
following a 500 mg twice daily regimen of Valacyclovir:  
2.0-4.0 mcg Acyclovir/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.